A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms

Digestive Diseases and Sciences

Volumn 61, Issue 2, 2016, Pages 560-571

  Cash, Brooks D ^a   Epstein, Michael S ^b   Shah, Syed M ^c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b Digestive Disorders Associates   (United States)

^c IM HealthScience LLC   (United States)

Author keywords

Abdominal pain; Bloating; Diarrhea; Irritable bowel syndrome; l menthol; Peppermint oil

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANXIOLYTIC AGENT; CENTRAL STIMULANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; COLCHICINE; LAXATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; OSMOTIC AGENT; PEPPERMINT OIL; PLACEBO; PROBIOTIC AGENT; SALICYLIC ACID DERIVATIVE; SPASMOLYTIC AGENT; TRAMADOL; VEGETABLE OIL;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACKACHE; BLOATING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAINFUL DEFECATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SMALL INTESTINE; SUSTAINED DRUG RELEASE; TOTAL IBS SYMPTOM SCORE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; IRRITABLE BOWEL SYNDROME; MIDDLE AGED;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PARASYMPATHOLYTICS; PLANT OILS;

EID: 84941330524     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3858-7     Document Type: Article

References (38)

1. Saito YA, Schoenfeld P, Locke GR III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910–1915.
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712–721.
3. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71–80.
4. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978;2:653–654.
5. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–1491.
6. Cappello G, Spezzaferro M, Grossi L, Manzoli L, Marzio L. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial. Dig Liver Dis. 2007;39:530–536.
7. European Medicines Agency. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. September 25, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/09/WC500173457.pdf. Accessed May 4, 2015.
8. Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43:541–550.
9. Drossman DA, Chang L, Bellamy N, et al. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011;106:1749–1759.
10. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40:1023–1034.
11. Thompson WG. Understanding the irritable gut: The functional gastrointestinal disorders. McLean, VA: Degnon and Associates; 2008:56–59.
12. Martinez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62:1160–1168.
13. Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol. 2011;46:421–431.
14. Martinez C, Vicario M, Ramos L, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. 2012;107:736–746.
15. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology. 1987;92:1885–1893.
16. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol. 2006;101:1288–1294.
17. Giamarellos-Bourboulis E, Tang J, Pyleris E, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50:1076–1087.
18. Salvioli B, Serra J, Azpiroz F, et al. Origin of gas retention and symptoms in patients with bloating. Gastroenterology. 2005;128:574–579.
19. Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988;2:101–118.
20. Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther. 2003;17:445–451.
21. Harries N, James KC, Pugh WK. Antifoaming and carminative actions of volatile oils. J Clin Pharm Ther. 1977;2:171–177.
22. Galeotti N, Di Cesare ML, Mazzanti G, Bartolini A, Ghelardini C. Menthol: a natural analgesic compound. Neurosci Lett. 2002;322:145–148.
23. Hawrelak JA, Cattley T, Myers SP. Essential oils in the treatment of intestinal dysbiosis: a preliminary in vitro study. Altern Med Rev. 2009;14:380–384.
24. Juergens UR, Stober M, Vetter H. The anti-inflammatory activity of L-menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases. Eur J Med Res. 1998;3:539–545.
25. Walstab J, Wohlfarth C, Hovius R, et al. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders. Neurogastroenterol Motil. 2014;26:810–820.
26. Enck P, Junne F, Klosterhalfen S, Zipfel S, Martens U. Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2010;22:1402–1411.
27. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109:S2–S26.
28. National Collaborating Center for Nursing and Supportive Care (UK). Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. 2008. http://www.ncbi.nlm.nih.gov/books/NBK51953/. Accessed May 4, 2015.
29. Lech Y, Olesen KM, Hey H, Rask-Pedersen E, Ostergaard O, Vilien M. Treatment of irritable bowel syndrome with peppermint oil. A double-blind study with a placebo. Ugeskr Laeger. 1988;150:2388–2389.
30. Merat S, Khalili S, Mostajabi P, Ghorbani A, Ansari R, Malekzadeh R. The effect of enteric-coated, delayed-release peppermint oil on irritable bowel syndrome. Dig Dis Sci. 2010;55:1385–1390.
31. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol. 1997;32:765–768.
32. Rees WD, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J. 1979;2:835–836.
33. Gelal A, Jacob P III, Yu L, Benowitz NL. Disposition kinetics and effects of menthol. Clin Pharmacol Ther. 1999;66:128–135.
34. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol. 1999;94:1320–1326.
35. Khanna R, MacDonald JK, Levesque BG. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. J Clin Gastroenterol. 2014;48:505–512.
36. Somerville KW, Richmond CR, Bell GD. Delayed release peppermint oil capsules (Colpermin) for the spastic colon syndrome: a pharmacokinetic study. Br J Clin Pharmacol. 1984;18:638–640.
37. European Medicines Agency. Guideline on quality of oral modified release products. March 20, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170465.pdf. Accessed May 4, 2015.
38. U.S.Department of Health and Human Services Food and Drug Administration. Guidance for industry irritable bowel syndrome– Clinical evaluation of drugs for treatment. 2012. http://www.fda.gov/downloads/Drugs/Guidances/UCM205269.pdf. Accessed March 29, 2015.